Law Updates

Subject

Summary: The Bureau of Indian Standards ( BIS ), on 23 July 2026, has come out with an updated notification through the BIS Rules, 2018, and adopted a total of 19 Indian Standards (IS) relating to various sectors such as leather safety footwear, combine harvesters, cement, wine analysis, irrigation pipes, and AYUSH pharmacovigilance, among others. The BIS notification 2026 has been made in the Gazette of India, Part III, Section 4, which will be effective from 21 July 2026. If your business manufactures, imports, tests, or sells products covered under any of these 19 standards, this update directly affects your compliance obligations. Many of these standards replace older specifications that are decades old, some dating back to 1970, 1979, 1982, 1983, 1985, and 1986, and businesses now have a fixed transition window before the old versions are formally withdrawn. This oversight could lead to products that do not meet the new requirements, shipment rejections, failure in BIS inspections, or even loss of certification. In this guide, we highlight every change in plain terms, clarify whom the changes affect, and list the precise actions your company must take to ensure compliance. If the process seems too complicated, professional regulatory assistance is available to help you navigate it. Key Highlights BIS issued Notification dated 23 July 2026. The notification was published under Rule 15(1) of the BIS Rules, 2018. 19 Indian Standards have been newly established or revised. All 19 standards came into effect on 21 July 2026. 16 of the 19 standards replace existing older Indian Standards. The older/superseded standards remain valid concurrently until they are formally withdrawn. The withdrawal date for most superseded standards is 21 January 2027, with a 6-month transition period. 3 standards (IS 19535, IS 19655 Part 6, and IS 19792) are entirely new, with no standard being withdrawn. One revision (IS 7328:2026) withdraws two older standards simultaneously: IS 7328:2020 and IS 10146:1982. Sectors affected include leather & footwear, glass, food additives, cement, laboratory instruments, plastics, wine testing, agricultural machinery, flour milling, telecom/radar towers, geotechnical engineering, irrigation equipment, paper, and AYUSH pharmacovigilance. Businesses using the withdrawn standards must transition their product specifications, testing protocols, and certification documentation before 21 January 2027. The Regulatory Framework The Bureau of Indian Standards is the organization responsible for setting National Standards of India in accordance with the provisions of the Bureau of Indian Standards Act, 2016. BIS is responsible for formulating, revising, and withdrawing Indian Standards on the quality, safety, and performance of products sold in the country. This notification is made under Sub-rule (1) of Rule 15 of BIS Rules, 2018, wherein BIS has been authorized to notify the creation of new or modified standards, as well as the date of withdrawal of old standards. Scope of this notification: The 19 standards span multiple technical divisions of BIS, so the update is not limited to a single industry. It covers consumer safety products (safety boots, safety glasses), food and pharma-adjacent items (food-grade cellulose, wine testing, pharmacovigilance), construction materials (cement, ground improvement, radar tower foundations), agricultural equipment (combine harvesters, flour milling, sprinkler irrigation), and general specifications (hydrometers, plastics, paper). What Has Changed Below is a structured comparison of every standard established under this notification against the standard it replaces (where applicable). S. No. New Standard (Effective 21 July 2026) Old Standard (Withdrawn 21 Jan 2027) 1 IS 1989 (Part 1):2026- Leather Safety Boots & Shoes, Part 1 for Miners (5th Revision) IS 1989 (Part 1)-1986 (4th Revision) 2 IS 1989 (Part 2):2026- Leather Safety Boots & Shoes, Part 2 for Heavy Metal Industries (5th Revision) IS 1989 (Part 2):1986 (4th Revision) 3 IS 2553 (Part 3):2026- Safety Glass, Part 3 Solar Applications (1st Revision) IS 2553 (Part 3):2019 4 IS 5306:2026- Sodium Carboxymethyl Cellulose, Food Grade (3rd Revision) IS 5306:1996 (2nd Revision) 5 IS 5867:2026- Leather Board for Footwear Insole (1st Revision) IS 5867-1970 6 IS 6452:2026- High Alumina Cement for Structural Use (2nd Revision) IS 6452:1989 (1st Revision) 7 IS 7324:2026- Brix Hydrometers (2nd Revision) IS 7324-1983 (1st Revision) 8 IS 7328:2026- Polyethylene (PE) Material for Moulding & Extrusion (3rd Revision) IS 7328:2020 (2nd Revision) and IS 10146-1982 9 IS 7585:2026- Wines, Methods of Test (2nd Revision) IS 7585:1995 (1st Revision) 10 IS 8122 (Part 1):2026- Combine Harvester, Terminology (2nd Revision) IS 8122 (Part 1):1994 (1st Revision) 11 IS 8122 (Part 2):2026- Combine Harvester, Test Code (2nd Revision) IS 8122 (Part 2):2000 (1st Revision) 12 IS 9374:2026- Flour Milling Industry, Glossary (1st Revision) IS 9374-1979 13 IS 11233:2026- Foundations for Radar/Satellite Antennas, Microwave & TV Towers (1st Revision) IS 11233-1985 14 IS 15284 (Part 1):2026- Ground Improvement, Stone Columns (1st Revision) IS 15284 (Part 1):2003 15 IS 15284 (Part 2):2026- Ground Improvement, Preconsolidation Using Vertical Drains (1st Revision) IS 15284 (Part 2):2004 16 IS 17425:2026- Quick Coupled PE Pipes & Fittings for Sprinkler Irrigation (1st Revision) IS 17425:2020 17 IS 19535:2026 (ISO 3036:2025)- Board, Puncture Resistance Using Pendulum Device NA (new standard) 18 IS 19655 (Part 6):2026- Handmade Paper, Part 6 for Certificates NA (new standard) 19 IS 19792:2026- Pharmacovigilance Centre for ASU&H Systems, Service Requirements NA (new standard) In simple words: Most of these are updated versions (revisions) of standards businesses were already following; some have been in use for over 40 years. The government has now modernised them. Three standards are entirely new and did not exist before. Implementation Timeline / Norms Understanding the timeline is the most critical part of this notification for compliance purposes. 21 July 2026:  Effective date of establishment for all 19 new/revised Indian Standards. 21 July 2026 to 21 January 2027:  Transition period. During this window, both the new standard and the corresponding old standard are simultaneously valid for the 16 revised specifications. 21 January 2027:  Withdrawal date. From this date, the older standards listed in column 4 of the schedule cease to have legal recognition, and only the new 2026 versions will apply. IS 19535:2026, IS 19655 (Part 6): 2026, and IS 19792:2026 have no transition requirements, as they are new standards with no withdrawn standards. Practical implications for businesses: They have a 6-month timeframe to change their product testing procedures, update their quality manuals, train quality control personnel, and, where necessary, obtain new BIS Licences/Certification Marks under the new standard numbers. Why Was This Implemented? BIS periodically reviews and revises Indian Standards to keep them aligned with current technology, international practice, and market needs. Based on the contents of this notification, the objectives include: Technical modernisation: several standards being replaced were 30-55 years old (e.g., IS 5867 from 1970, IS 9374 from 1979, IS 10146 from 1982) and needed updates to reflect current materials and manufacturing methods. International harmonisation: IS 19535:2026 is directly aligned with ISO 3036:2025, showing BIS's continued effort to align Indian Standards with global ISO benchmarks. Worker and consumer safety: the revised leather safety boot standards (IS 1989 Parts 1 & 2) protect workers in the mining and heavy metal industries, reflecting ongoing occupational safety priorities. New sectoral coverage: the introduction of a dedicated pharmacovigilance service standard (IS 19792) for Ayurveda, Siddha, Sowa-Rigpa, Unani, and Homoeopathy (ASU&H) systems reflects the growing regulatory focus on traditional medicine safety monitoring. Documentation standardisation: a new standard for handmade paper used specifically for certificates (IS 19655 Part 6) supports consistent quality in official/ceremonial paper products. Impact on Businesses Manufacturers: Any manufacturer producing leather safety footwear, high alumina cement, PE pipes/materials, combine harvesters, or safety glass must update their manufacturing and testing processes to conform to the 2026 specifications before the old standards are withdrawn. Importers: Companies importing the polyethylene materials, safety glass used in solar technology, or laboratory equipment such as Brix hydrometers must ensure that the IS numbers listed in the supplier's certification and documentation were updated before 2027. Exporter: Exporters using BIS certification as a quality measure should take steps now to update the cited standards to avoid any dispute regarding their validity. Brand Owners & BIS Licence Holders: Companies holding a BIS Licence (under the Scheme of Testing and Inspection) for any of the 16 revised standards will likely need to apply for licence amendment to reflect the new IS number and revised technical parameters. MSMEs & Startups: Smaller manufacturers of items such as leather board insoles, agricultural equipment components, or irrigation pipes and fittings often have limited in-house regulatory teams this makes early action and expert guidance particularly valuable to avoid last-minute compliance gaps. Testing Laboratories: Laboratories conducting tests related to wine analysis, hydrometers, and plastics will require new testing methods that comply with the revised standards. Construction and Infrastructural Organizations: Organizations engaged in foundation design for radar/telecommunication towers and in ground improvement activities, such as stone column and vertical drain construction, will require the use of the new code of practice standards IS 11233:2026 and IS 15284 Parts 1 and 2. Manufacturers of Agricultural Machinery: Manufacturers of combine harvesters will require changes in terminology and testing codes that conform to the standard IS 8122 (Parts 1 and 2):2026. AYUSH Sector Enterprises: Pharmacovigilance centres within the Ayurveda, Siddha, Sowa-Rigpa, Unani, and Homoeopathy systems will require a new service requirement standard (IS 19792:2026). How Businesses Will Achieve Compliance? A practical, step-by-step roadmap: Identify applicability:  Check whether your product, material, or service falls under any of the 19 standards listed above. Review the new standard document:  Obtain the full text of the relevant 2026 IS standard from BIS to understand the exact technical changes from the previous version. Gap analysis:  Compare your current product specifications, manufacturing process, and test reports against the new requirements to identify gaps. Update internal documentation:  Revise quality manuals, standard operating procedures (SOPs), and product datasheets to reference the correct 2026 standard number. Amend BIS licence/certification:  If you hold a BIS Licence or Certification Mark linked to an old standard, apply for an amendment or renewal referencing the new IS number before 21 January 2027. Retest products:  Where technical parameters have changed, get products re-tested in a BIS-recognised or NABL-accredited laboratory against the new standard. Train quality control staff:  Ensure QC and production teams understand the revised parameters, especially for safety-critical items like footwear and safety glasses. Update supplier and vendor contracts:  For importers and traders, ensure supplier agreements specify compliance with the 2026 standard. Maintain records:  Keep documentary evidence of the transition (old and new test reports, correspondence with BIS) for at least the transition period plus a reasonable buffer. Track the withdrawal date:  Mark 21 January 2027 as a hard compliance deadline for phasing out reliance on the older standard. Common mistakes to avoid: Continuing to reference the old IS number on product labels or certificates after the withdrawal date. Assuming the six-month transition period means no action is needed until the deadline. Overlooking licence amendment requirements when only the standard number (not the product itself) has changed. Not verifying whether a standard was withdrawn by a single replacement or, as in the case of IS 7328:2026, by two separate older standards. Benefits for Businesses Legal compliance and avoidance of penalties or product seizure for non-conforming goods. Reduced risk of shipment rejection for exporters relying on updated BIS-marked products. Improved consumer and buyer trust through demonstrably current, internationally aligned standards. Smoother government tender participation, since public procurement frequently mandates current BIS standards. Operational efficiency from updated, more relevant technical specifications. Competitive advantage for early adopters who transition ahead of the January 2027 deadline. Right Decision or Additional Burden? For most businesses, this change is just a periodic, mandatory regulatory update rather than a disruptive one. A six-month window of concurrent validity is a practical and business-friendly process for making such changes; it does away with the problems caused by the unexpected withdrawal of standards. However, companies should be mindful of the administrative costs of updating documents, testing products, and renewing BIS licenses, as these processes take time. There are delays in obtaining a BIS license , and companies running up against the January 2027 deadline may fall into the trap of a compliance issue. Overall, it would be wiser to treat this as a chance for system improvement. Business Opportunities Created Testing and certification demand:  laboratories and certification bodies may see increased business as manufacturers seek re-testing against the new standards. Consulting and compliance services:  businesses without in-house regulatory expertise create demand for compliance consultancies to manage licence amendments and documentation. Export market access: updated, internationally aligned standards (such as IS 19535 aligned with ISO 3036:2025) can strengthen the credibility of Indian products in global markets. New AYUSH sector formalisation: the pharmacovigilance service standard opens opportunities for ASU&H healthcare entities to formally structure and certify their safety monitoring operations. Quality upgrade cycles: manufacturers upgrading equipment/processes to meet new standards may also modernise broader production capabilities. Why Choose Corpseed? Navigating a multi-sector BIS notification like this one with different deadlines, licence amendment requirements, and technical parameters across 19 separate standards can be time-consuming for internal teams. Corpseed supports businesses through the entire compliance lifecycle, including: BIS Licence and Certification Mark application and amendment Gap analysis between old and new Indian Standards Coordination with BIS-recognised testing laboratories End-to-end documentation preparation and filing. Liaison with BIS regional and head offices Renewal and periodic compliance tracking Pan-India support for manufacturers, importers, and exporters across all sectors covered under this notification Our team works directly with businesses to convert a complex regulatory notification into a simple, actionable transition plan so you can focus on production and growth. At the same time, compliance is handled correctly and on time. Corpseed's Core Message Changes such as those in the BIS notice can easily go unnoticed until there is cargo detention, non-conformity during inspections, or denial of license renewal due to citing an obsolete standard. It will be better to act now rather than wait until 21 January 2027, when the standard expires. If your business manufactures, imports, tests, or certifies any product covered under these 19 revised Indian Standards, now is the right time to review your compliance position. Corpseed's regulatory experts can assess your exposure, manage your BIS licence amendments, and guide you through a smooth transition to the new standards. Get in touch with our team today. Conclusion The current BIS notification, published on 23rd July 2026, sets 19 new or amended Indian Standards for different sectors, which will be applicable as of 21st July 2026. It also provides a clear transition period until 21st January 2027 for 16 Indian standards that will be replaced. Companies engaged in the production of leather products, safety glass, cement, plastics, agricultural machinery, irrigation, construction, and AYUSH should assess their product specifications and testing criteria, as well as their BIS licences, before the deadline. Doing this in advance will save you from compliance risks, licence rejections, and shipment delays. If you need any help understanding the applicability of the notification and amending your BIS licence, our team of professionals at Corpseed will provide you with complete assistance.

Subject

Summary: On 11th June 2026, the Ministry of Health and Family Welfare banned the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs across India. This fixed dose combination drug ban 2026 was issued through 16 separate notifications under Section 26A of the Drugs and Cosmetics Act, 1940, and published in the Gazette of India on 15th June 2026. If your business produces, markets, imports, or distributes any medicine in India, then this news update affects you. A prohibition order is not issued regularly. This means that the production, sale, and distribution of such combinations after the date of issuance of the notice becomes illegal. This article aims to provide simple information about the changes, the government's rationale for the decision, the combination involved, and the actions to be taken by pharma manufacturers, formulators, distributors, and retailers. The guidance becomes more complex when reformulation, stock reduction, or other regulatory issues are involved; therefore, it is necessary to consult a professional at Corpseed in such cases. Key Highlights The Central Government has prohibited the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs for human use, with immediate effect. The ban was issued through notifications S.O. 3068(E) to S.O. 3083(E), dated 11th June 2026, published in the Gazette of India on 15th June 2026. The legal basis is Section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), which empowers the Central Government to prohibit a drug when it is satisfied that its use poses a risk to human beings and safer alternatives exist. The banned list includes well-known combinations involving Amoxicillin, Cefadroxyl, Cefuroxime, Dicyclomine, Paracetamol, Gliclazide, as well as several Aloe Vera- and herbal-based fixed-dose combinations. Every combination was first flagged by an Expert Committee in 2021, which found them "irrational" for lacking supporting scientific and peer-reviewed evidence. The Drugs Technical Advisory Board (DTAB) examined the Expert Committee's findings and, in principle, agreed with the recommendation. A Sub-Committee of DTAB was formed to examine each combination in detail and allowed manufacturers and stakeholders to submit data through public notices. The Sub-Committee submitted its final report on 28th December 2024, recommending prohibition in the larger public interest. The order takes effect immediately from the date of notification there is no transition or sell-through period mentioned in the notifications. Businesses currently manufacturing, marketing, or holding stock of any of these 16 combinations must cease operations related to these combinations and review their regulatory position without delay. The Regulatory Framework Applicable Law These notifications are made under Section 26A of the Drugs and Cosmetics Act, 1940. Section 26A grants the Central Government the authority to prohibit the manufacture, sale, or distribution of any drug if it believes the drug is likely to be hazardous to humans, there are safer alternatives available, or it is not therapeutic. What Is a "Fixed Dose Combination" (FDC)? A fixed-dose combination is a single pharmaceutical product that contains two or more active ingredients in a fixed dose ratio. FDCs are common because they can improve patient compliance (fewer pills to take). Still, if the ingredients lack sound scientific justification for combination, they can pose unnecessary risks without added therapeutic benefit. This is precisely the concern raised across all 16 notifications. Scope These prohibitions apply nationwide and cover manufacture, sale, and distribution for human use. There is no exemption carved out in the notifications for existing stock, export-only production, or specific states. What Has Changed: The Full List of Banned FDCs Each of the 16 notifications follows the same regulatory process but applies to a different drug combination. Here is the complete list with their notification numbers: S.O. Notification Fixed Dose Combination S.O. 3068(E) Acetyl Salicylic Acid + Ethoheptazine S.O. 3069(E) Aloe vera + Jojoba oil + Wheat germ oil + Tea tree oil S.O. 3070(E) Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes S.O. 3071(E) Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide S.O. 3072(E) Amoxicillin + Serratiopeptidase S.O. 3073(E) Aloe Extract + Allantoin + Alphatocopherol Acetate + D-Penthenol + Vitamin A S.O. 3074(E) Aloe Extract + Vitamin E + Dimethicone + Glycerine S.O. 3075(E) Aloe Vera + Jojoba Oil + Vitamin E S.O. 3076(E) Aloe vera + Orange oil S.O. 3077(E) Aloe vera + Vitamin E + Herbal S.O. 3078(E) Dicyclomine + Paracetamol + Clidinium Bromide S.O. 3079(E) Paracetamol + Lignocaine S.O. 3080(E) Gliclazide + Chromium Picolinate S.O. 3081(E) Amoxicillin + Cloxacillin + Lactic acid bacillus + Serratiopeptidase S.O. 3082(E) Cefadroxyl + Probenecid S.O. 3083(E) Cefuroxime + Serratiopeptidase Previous Position vs New Position Aspect Before June 2026 After June 2026 Legal status of these 16 FDCs Legally manufactured, marketed and sold, subject to existing drug licences Manufacture, sale, and distribution prohibited for human use Basis for review Combinations flagged as "irrational" by Expert Committee (2021) under evaluation Formal prohibition following Sub-Committee report (Dec 2024) and DTAB recommendation Manufacturer/stakeholder input Opportunity given through public notices during Sub-Committee review Review concluded; prohibition already notified Effective date N/A Immediate effect from date of notification (11th June 2026) Common Reasons Cited Across the Notifications While each combination has its own specific finding, a few recurring reasons appear across the 16 notifications: No sound clinical or pharmacodynamic justification for combining certain active ingredients (for example, antibiotic combinations with enzyme preparations like Serrati peptidase, where the committee found no solid clinical evidence supporting concurrent use). Lack of peer-reviewed scientific evidence supporting the rationality of the combination. Deviation from standard treatment guidelines, both national and international (as seen in the Gliclazide + Chromium Picolinate combination, where standard Type 2 Diabetes treatment guidelines do not recommend Chromium Picolinate). Undefined or uncharacterized products, particularly among several Aloe vera and herbal-based topical combinations, where the committee noted the product itself was not well defined. Absence of pharmacokinetic data to justify dose combinations, as seen in the Cefadroxyl + Probenecid notification. Risk exceeding benefit in the larger public interest, even where individual ingredients may be safe on their own. Implementation Timeline / Norms Effective Date All 16 notifications state that the prohibition applies "with immediate effect" from the date of the notification, i.e., 11th June 2026. No Stated Transition Period Unlike some regulatory changes that allow a grace period to liquidate existing stock or transition to alternate formulations, these notifications do not mention any sell-through or transition window. This makes immediate compliance review critical. Regulatory Process Timeline (For Context) Understanding how this ban evolved can help businesses anticipate future FDC reviews: 2021:  Expert Committee examines each FDC and finds them "irrational." Post-2021:  DTAB reviews the Expert Committee's findings and agrees in principle. DTAB Sub-Committee formed:  tasked with detailed examination of all irrational FDCs. Public notices issued:  Manufacturers and stakeholders allowed to submit precise data defending the combination. 28th December 2024:  Sub-Committee submits its final report recommending prohibition. DTAB agrees with the Sub-Committee's recommendation. 11th June 2026:  Central Government issues the final prohibition notifications under Section 26A. This roughly five-year process shows that FDC reviews in India move through multiple layers of expert scrutiny before a ban is finalised, which also means businesses holding FDC licences should track ongoing DTAB reviews proactively rather than waiting for a final notification. Why Was This Implemented? The government's stated objective across all 16 notifications is consistent: protecting public health by removing drug combinations that carry risk without adequate therapeutic justification, especially where safer alternatives already exist. Key objectives include: Patient safety:  removing combinations where the risk-benefit balance does not favour the patient. Scientific rigour in drug approval:  ensuring that combination drugs are backed by real clinical evidence, not just commercial convenience. Rational use of medicines:  aligning with India's broader effort (going back to earlier FDC bans in 2016 and subsequent years) to clean up the market of combinations that lack a sound pharmacological basis. Alignment with standard treatment guidelines:  as seen with the Gliclazide + Chromium Picolinate case, where the combination did not match national or international treatment protocols. Preventing irrational polypharmacy:  several banned combinations added ingredients (such as enzymes or vitamins) to established drugs without clear added benefit, increasing exposure to side effects unnecessarily. Impact on Businesses Manufacturers:  Manufacturers currently producing any of the 16 listed FDCs must immediately halt production. Continuing to manufacture a prohibited drug can expose the company to penal action under the Drugs and Cosmetics Act, including seizure of stock and cancellation of related manufacturing licences. Importers:  If any of these combinations are imported into India in finished or bulk form, import of the prohibited combinations must stop. Import licences tied specifically to these formulations will need to be reviewed and, where applicable, surrendered or amended. Exporters:  The notices specifically limit manufacture, sale, and distribution for human consumption in that country. Firms that export such combinations need to carefully consider whether an export manufacturing operation is feasible, since the export business remains subject to India's regulations and manufacturing laws. Brand Owners and Marketing Companies:  Brand owners who outsource manufacturing (loan licensing/third-party manufacturing arrangements) are equally responsible for compliance. Marketing and promotional activity for these brands must stop immediately, including trade communication, MR (medical representative) detailing, and e-pharmacy listings. MSMEs and Startups:  Smaller pharmaceutical manufacturers, often reliant on a narrower product portfolio, may feel a sharper financial impact from a sudden ban. MSMEs should prioritise a rapid compliance review to avoid inventory write-offs that could lead to legal exposure. Large Enterprises:  Larger pharma companies with wide product portfolios should still treat this as serious regulatory non-compliance; even one SKU can trigger scrutiny of the entire manufacturing licence and facility. Traders, Distributors, and Retailers:  Anyone holding existing stock of these 16 combinations from stockists to retail pharmacies should stop further sale and consult with their supplier or a regulatory expert on the appropriate way to handle existing inventory. Service Providers (Formulation Developers, CROs, CDMOs):  Contract development and manufacturing organisations (CDMOs) and formulation R&D teams working on any of these combinations, or structurally similar combinations, should reassess ongoing projects in light of the reasoning given in these notifications, since similar combinations may face similar scrutiny in future DTAB reviews. How will Businesses achieve Compliance? The following is a compliance roadmap for businesses impacted by the notification: Step 1: Verification of Impact Verify whether you fall within the scope of the notification by cross-verifying your product range, active pharmaceutical ingredients used, and drug manufacturing licence (Form 25/28). Variations in the ratio or additional inclusion of ingredients may still place your business within the scope of this notification. Step 2: Immediate Suspension of Production, Sales and Distribution Since the ban is immediate, businesses cannot plan for a gradual closure. The manufacture, marketing material, and distribution must be stopped immediately. Step 3: Modification of your Manufacturing Licences Your manufacturing licence (form 25/28) might require modification, as the banned combination must be removed from the approved products under your licence. Step 4: Disposal of existing Stock It cannot be assumed that stock manufactured earlier is exempt from this ban. Seek advice from the State Drug Control Authority regarding proper disposal or recall procedure. Step 5: Communication to Distribution Network Send a communication about the ban to your distribution channel so the product is removed from sales channels. Step 6: Review of Research Pipeline If your research pipeline includes other combinations that have been banned, reconsider the scientific justification based on the DTAB findings before progressing further. Step 7: Documentation Document all compliance measures in case any scrutiny happens in the future. Common Compliance Mistakes to Avoid Assuming a "grace period" exists when the notification says "immediate effect." Continuing to sell existing inventory without checking with the licensing authority. Overlooking loan-licensing or third-party manufacturing arrangements when assessing exposure. Failing to update marketing and e-commerce/e-pharmacy listings promptly. Not documenting the compliance actions taken, which can matter significantly during inspections. If you're unsure whether your product formulation matches a banned combination exactly (for example, a similar but not identical ratio), don't self-assess. A regulatory consultant can help you interpret the notification in the context of your specific product dossier and avoid both over-compliance (unnecessarily halting a legal product) and under-compliance (continuing to market an illegal one). Benefits for Businesses That Get Compliance Right While a ban is disruptive, businesses that respond to it correctly and quickly stand to gain in several ways: Avoiding penalties and legal action under the Drugs and Cosmetics Act. Protecting manufacturing licences from suspension or cancellation risk tied to a single non-compliant product. Maintaining market and distributor trust, since a swift, professional response signals regulatory maturity. Freeing up R&D and manufacturing capacity to reformulate or pivot to compliant, evidence-backed alternatives. Reducing future regulatory risk by using this as an opportunity to review the rest of the product portfolio for similar irrational combinations. Smoother business continuity by acting early rather than waiting for a regulatory notice or inspection. Right Decision or Additional Burden? It's fair to look at this from both sides. From a public health standpoint, the ban is a reasonable and evidence-based decision. Each of the 16 combinations underwent a multi-year review, an Expert Committee assessment, a DTAB evaluation, a dedicated Sub-Committee review, and an opportunity for manufacturers to submit data before the final prohibition. That is a considerably more thorough process than an abrupt regulatory decision. As far as the business implications of the notification go, the lack of any phase-in period to ease the compliance process can pose practical problems: from excess stock to the need for immediate licence changes, all of which pose real obstacles. The balanced perspective: regarding the regulatory intent behind the notification itself, it is clearly a good move to eliminate drug combinations lacking scientific evidence. However, the time frame set by the regulators poses a challenge for those businesses that operated within legal boundaries until the announcement was made. Business Opportunities Created A regulatory disruption like this also opens doors: Reformulation opportunities- Companies can develop scientifically justified alternatives to replace the banned combinations, potentially capturing market share vacated by the ban. Consulting demand- Pharma companies across the country will need regulatory support to interpret and act on this notification, creating opportunities for compliance consultants and legal advisors. Portfolio review as a competitive edge- Companies that proactively audit their full portfolio against DTAB's ongoing "irrational FDC" review process can position themselves ahead of future bans. Trust-building with regulators- Businesses that respond transparently and promptly to this notification build long-term credibility with licensing authorities, which can smooth future approvals. Export and manufacturing realignment- Companies can use this as a trigger to review and modernise their broader manufacturing and product strategy. Why Choose Corpseed? Navigating a sudden regulatory prohibition like this is not something to handle informally. Corpseed works with pharmaceutical manufacturers, importers, and distributors across India on: End-to-end regulatory compliance support for drug licensing under the Drugs and Cosmetics Act, 1940 Manufacturing licence review, amendment, and renewal assistance Documentation support for stock recall, licence surrender, or product discontinuation Guidance on reformulation and fresh product approval pathways. Liaison support with State Drug Control Authorities and the Central Drugs Standard Control Organisation (CDSCO). Application filing for new drug approvals and licence modifications. Pan-India support for businesses operating across multiple states with different licensing authorities. Dedicated regulatory experts who track ongoing DTAB reviews so you're not caught off guard by future FDC prohibitions A transparent, structured process with clear timelines, so you know exactly where your compliance stands at every stage. Whether you need to urgently amend a manufacturing licence, manage existing stock of a banned FDC, or explore compliant reformulation options, Corpseed's regulatory team can guide you through the process without unnecessary delays. Corpseed's Core Message Regulatory notifications like this one don't leave room for a "wait and watch" approach. The prohibition is already in effect, and the risk of continuing to manufacture, sell, or distribute any of these 16 combinations grows with every day of inaction. If your business is affected even partially, even though a third-party manufacturing arrangement is the smartest move, it is to get a clear, expert read on your exposure before it becomes a compliance issue. Delayed action on drug prohibitions can lead to stock seizures, licence suspension, and reputational damage that takes far longer to repair than the compliance process itself. Corpseed's regulatory consultants can help you assess your exposure, manage the transition, and get your documentation in order so you can focus on running your business. At the same time, the compliance side is handled by people who track these notifications for a living. Talk to a Corpseed regulatory expert today to review your product portfolio against this notification and stay ahead of future FDC reviews.

Subject

Summary: The Central Government has proposed the Indian Insurance Companies (Inquiry, Adjudication and Appeal) Rules, 2026 to establish a structured process for handling violations, penalties, and appeals under the General Insurance Business (Nationalisation) Act, 1972. The draft rules provide a clear framework for filing complaints, conducting inquiries, passing adjudication orders, determining penalties, and allowing appeals against such orders. The proposed framework aims to bring more consistency and transparency to regulatory enforcement concerning Indian insurance companies. For insurance companies the development is important because it introduces a defined compliance process where violations under the Act can lead to formal inquiry proceedings, penalties and appellate review. Businesses should understand the proposed mechanism and prepare their compliance systems accordingly. What This Draft Notification Is About and When It Was Issued The Ministry of Finance, Department of Financial Services, has published the draft rules for public consultation before their final notification in the Gazette of India. The draft rules have been proposed under the powers provided by: Sub-sections (1) and (2) of Section 30A of the General Insurance Business (Nationalisation) Act, 1972. Clauses (ea) and (eb) of sub-section (2) of Section 39 of the Act. The Government has invited objections and suggestions from persons likely to be affected by the proposed rules. The final rules will be published after considering the feedback received during the consultation period. Key details of the draft rules: Particulars Details Name of Rules Indian Insurance Companies (Inquiry, Adjudication and Appeal) Rules, 2026 Issuing Authority Ministry of Finance, Department of Financial Services Applicable Law General Insurance Business (Nationalisation) Act, 1972 Purpose To establish procedures for inquiry, adjudication and appeals Effective Date Date of publication in the Official Gazette after finalisation What Are the Indian Insurance Companies (Inquiry, Adjudication and Appeal) Rules, 2026? The proposed rules create a formal mechanism for dealing with violations committed by Indian insurance companies under the General Insurance Business (Nationalisation) Act, 1972. Before these rules, the Act provided the authority to take action for certain violations, but the detailed procedure for conducting inquiries, issuing notices, considering evidence, imposing penalties and filing appeals required a structured framework. The draft rules establish procedures for: Filing complaints against violations. Conducting inquiries through an adjudicating officer. Providing an opportunity to explain and submit evidence. Passing penalty orders after considering relevant factors. Filing appeals against adjudication orders. The framework aims to ensure that regulatory action follows a defined process rather than being handled without procedural clarity. Why the Government Proposed a New Inquiry and Adjudication Framework The proposed framework is intended to improve the enforcement process under the General Insurance Business (Nationalisation) Act, 1972. A structured inquiry and appeal mechanism helps ensure that: Insurance companies receive a fair opportunity to present their position. Regulatory violations are examined through a defined process. Penalties are decided after considering relevant circumstances. Businesses have a formal channel to challenge adjudication orders. The rules also bring greater clarity regarding the roles of the Adjudicating Officer and the Appellate Authority. For insurance companies, this means regulatory compliance will require stronger documentation, timely responses to notices, and proper maintenance of records related to statutory obligations. Key Provisions Introduced Under the Draft Insurance Rules, 2026 The draft rules introduce several important procedures that will govern inquiry and penalty proceedings. 1. Complaint Filing Mechanism An Indian insurance company can file a complaint against a violation under Section 29 of the Act before the adjudicating officer. The complaint can be submitted: Through electronic means as notified by the Government. Physically through speed post. By hand submission. The complaint must be filed in the prescribed Form-I. 2. Appointment of Adjudicating Officer The Central Government will appoint an adjudicating officer under Section 30A of the Act. The officer will be responsible for: Conducting inquiries. Examining evidence and documents. Providing opportunities to affected parties. Passing final adjudication orders. 3. Notice and Opportunity to Respond Before conducting an inquiry, the adjudicating officer must issue a notice requiring the concerned person to explain why an inquiry should not be initiated. The notice must: Mention the alleged violation. Provide details of the applicable provisions. Give at least fourteen days to submit a response. 4. Evidence and Hearing Process During the inquiry, the concerned person will get an opportunity to: Appear personally or through an authorised representative. Submit documents and evidence. Present their explanation regarding the alleged violation. The adjudicating officer can continue proceedings if a person fails to appear after receiving proper notice. Powers Granted to the Adjudicating Officer under the Proposed Rules To ensure inquiries are conducted fairly and efficiently, the draft rules grant the adjudicating officer powers similar to those exercised by a civil court under the Code of Civil Procedure, 1908. These powers enable the officer to gather relevant information, examine evidence and make informed decisions while conducting inquiry proceedings. The adjudicating officer will have authority to: Summon and examine individuals involved in the proceedings. Require the production of documents and other relevant materials. Accept evidence submitted through affidavits. Request public records from government offices. Issue directions for examination of witnesses or documents. Exercise other prescribed powers required for conducting the inquiry. These powers are intended to help the adjudicating officer examine violations based on proper evidence and maintain a fair inquiry process. For insurance companies, this highlights the importance of maintaining accurate records, compliance documents, and timely responses during regulatory proceedings. How Penalties Will Be Determined Under the New Insurance Framework If the adjudicating officer concludes that a violation has occurred under the Act, a penalty may be imposed as provided under Section 30 of the General Insurance Business (Nationalisation) Act, 1972. The penalty decision will not be based only on the existence of a violation. The adjudicating officer will consider various factors before deciding the penalty amount. The factors include: Factor Considered Impact on Penalty Assessment Disproportionate gain or unfair advantage Whether the person gained financially from the violation Loss caused to the Indian Insurance Company Extent of financial impact caused by the violation Repeated violations Whether similar violations occurred previously Nature, seriousness and duration of violation Severity and period of non-compliance Steps taken to reduce the impact Actions taken to correct the issue Other relevant factors Additional circumstances considered appropriate This approach creates a more structured penalty assessment process and allows the circumstances of each case to be considered before imposing a penalty. Appeal Process against Orders Issued by the Adjudicating Officer The draft rules provide an appeal mechanism for any person affected by an order passed by the adjudicating officer. An appeal can be filed before the appellate authority appointed by the Central Government. Key requirements for filing an appeal: The appeal must be filed within 30 days from the date of the adjudicating officer’s order. The appellate authority may accept delayed appeals if sufficient reasons are provided. The appeal must include: Copy of the adjudication order. Statement of facts. Grounds for appeal. Relevant provisions of the Act. The appeal can be submitted: Personally. Through an authorised representative. By registered post or speed post. Through electronic means. After reviewing the submissions and providing both parties an opportunity to be heard, the appellate authority will pass an appropriate order. The appellate authority is required to dispose of the appeal within 60 days from the date of admission of the appeal. Compliance Impact of the Draft Rules on Indian Insurance Companies The proposed rules introduce a more formal compliance process for insurance companies operating under the General Insurance Business (Nationalisation) Act, 1972. While the rules primarily establish procedures for inquiry and adjudication, they will increase the importance of internal compliance monitoring and documentation. Key compliance areas businesses should focus on: 1. Maintaining Regulatory Records Insurance companies should maintain proper records related to: Statutory obligations under the Act. Regulatory communications. Internal compliance reviews. Corrective actions taken after identifying issues. Proper documentation will help businesses respond effectively if any inquiry is initiated. 2. Timely Response to Regulatory Notices The draft rules provide specific timelines for responses and submissions. Companies should establish internal processes to: Track regulatory notices. Assign responsibility for responses. Review legal and compliance submissions before filing. Delays in responding may affect the ability of businesses to present their position during proceedings. 3. Strengthening Compliance Controls Insurance companies may need to review their existing compliance frameworks to identify possible gaps. This includes: Periodic compliance assessments. Internal audits. Employee awareness regarding statutory requirements. Record management systems. A stronger compliance structure can help reduce the risk of violations and penalties. What Insurance Companies Need to Do to Prepare for the New Framework Although the rules are currently in draft form, insurance companies should begin preparing for a more structured regulatory enforcement environment. Businesses should consider the following steps: 1. Review Existing Compliance Practices: Companies should evaluate whether their current processes align with obligations under the General Insurance Business (Nationalisation) Act, 1972. 2. Strengthen Documentation Systems: Maintain organised records of: Regulatory filings. Approvals. Internal reviews. Compliance actions. 3. Establish Regulatory Response Mechanisms: Companies should define: Responsible teams for handling notices. Escalation procedures. Timelines for submitting responses. 4. Monitor Final Notification: As the rules are still in the draft stage, businesses should monitor further updates from the Ministry of Finance and prepare for their implementation after the final notification is issued. Key Compliance Timeline under the Draft Insurance Rules, 2026 Activity Timeline Submission of objections and suggestions on draft rules Within 30 days from availability of draft rules Response to show cause notice issued by adjudicating officer Within 30 days from availability of draft rules Filing appeal against adjudication order Within 30 days from order date Filing appeal against adjudication order Within 30 days of receiving notice Disposal of admitted appeal Within 60 days from admission Potential Benefits of the New Inquiry and Appeal Framework The proposed rules establish a defined procedure for handling inquiries, adjudication and appeals, which can make regulatory enforcement more structured and predictable for insurance companies. Improved Regulatory Clarity: The rules outline how complaints, inquiries, penalties, and appeals will be handled, helping businesses better understand the enforcement process. Improved Regulatory Clarity: A defined process for inquiry, penalty assessment, and appeals can reduce uncertainty regarding enforcement actions. Fair Opportunity to Present Defence: Companies will have a formal opportunity to submit explanations, documents and evidence before penalties are imposed. Consistent Penalty Decisions: By specifying factors for penalty determination the rules aim to create more consistent enforcement practices. Better Accountability: A structured mechanism may encourage insurance companies to strengthen compliance systems and maintain better regulatory discipline. Challenges and Compliance Risks for Insurance Companies Although the draft rules provide greater procedural clarity, they also place more responsibility on insurance companies to handle regulatory proceedings in a timely and organised manner. Some practical challenges businesses may face include: Preparing timely responses to notices issued by the adjudicating officer, as the rules prescribe specific timelines for submitting explanations and supporting documents. Maintaining sufficient evidence to support their position during an inquiry, particularly where regulatory compliance or corrective actions need to be demonstrated. Managing inquiry proceedings by coordinating legal, compliance, and business teams to ensure complete and accurate submissions before the adjudicating officer. Meeting procedural requirements while filing appeals, including preparing the prescribed forms, supporting documents and grounds for appeal within the specified time. Reviewing internal compliance practices to minimise the possibility of regulatory violations that could lead to inquiry proceedings or financial penalties. Is the Proposed Insurance Adjudication Framework the Right Approach? The draft rules mainly focus on establishing a standard procedure for inquiry, adjudication, and appeal proceedings under the General Insurance Business (Nationalisation) Act, 1972. A clearly defined process can make regulatory enforcement more consistent while giving insurance companies a better understanding of how such proceedings will be conducted. Key Advantages of the Proposed Framework Aspect Impact on Insurance Companies Clear enforcement process A defined procedure for inquiries and penalties can reduce uncertainty around regulatory actions. Opportunity to present a defence Companies will get a formal opportunity to submit explanations, documents, and evidence before penalties are imposed. Consistent penalty assessment Consideration of factors such as the nature of violation, financial impact, and corrective actions can support more balanced decisions. Compliance Areas Requiring Attention Insurance companies may need to review how they handle regulatory proceedings and maintain compliance records. Particular attention may be required in the following areas: Reviewing internal processes for responding to regulatory notices and inquiry proceedings. Maintaining documents and records that may be required to support submissions during an inquiry. Establishing clear responsibilities for preparing responses, coordinating with authorised representatives, and managing appeal-related documentation. Tracking statutory timelines for replying to notices and filing appeals to avoid procedural delays. While the proposed framework strengthens regulatory enforcement, it also provides businesses with a defined process to present their case before any penalty is imposed. Companies that maintain proper records and follow the prescribed procedures are likely to be better prepared to manage regulatory proceedings. How Corpseed Can Help Businesses with Insurance Regulatory Compliance The introduction of the Indian Insurance Companies (Inquiry, Adjudication and Appeal) Rules, 2026 may require insurance companies to strengthen their compliance and regulatory response systems. Corpseed can support businesses through: 1. Regulatory Compliance Assessment Corpseed can help insurance companies review their existing compliance framework and identify potential gaps under applicable regulatory requirements. Support areas include: Compliance process review. Documentation assessment. Regulatory obligation mapping. 2. Regulatory Documentation Support Businesses may require assistance in preparing and organising compliance documents during regulatory proceedings. Support can include: Review of supporting documents.  Compliance records management.  Submission preparation assistance.  3. Inquiry and Adjudication Support Companies facing regulatory inquiries may require professional guidance to manage proceedings effectively. Support areas include: Understanding notices.  Preparing responses.  Organising evidence and supporting records.  Coordinating compliance submissions.  4. Appeal and Regulatory Representation Assistance Where businesses wish to challenge an adjudication order, professional support can help in: Reviewing grounds for appeal.  Preparing required documentation.  Managing procedural requirements.  5. Ongoing Regulatory Monitoring Since insurance regulations continue to evolve, businesses can benefit from regular monitoring of: Government notifications.  Regulatory amendments.  Compliance obligations.

Subject

Summary: The Central Government has notified the Minerals (Other than Atomic and Hydro Carbons Energy Minerals) Concession (Fourth Amendment) Rules, 2026 under Section 13 of the Mines and Minerals (Development and Regulation) Act, 1957. The amended rules will come into effect from 1 August, 2026. The amendment changes certain provisions of the Minerals (Other than Atomic and Hydro Carbons Energy Minerals) Concession Rules, 2016. It removes Rule 34 and Schedule XII and replaces Rule 54 with a revised penalty provision linked to Sections 25A and 25B of the MMDR Act and the Mines and Minerals Adjudication of Penalties Rules, 2026. The update mainly affects how violations under the concession rules will be handled. It does not introduce any new licence requirements or changes to mining operations. Instead, it provides a revised process for imposing penalties and managing non-compliance under the existing mining regulatory framework. What Exactly Has Changed Under the Fourth Amendment Rules, 2026 The Fourth Amendment introduces three key changes to the Minerals (Other than Atomic and Hydro Carbons Energy Minerals) Concession Rules, 2016, all of which will take effect from 1 August 2026. The key amendments are: Rule 34 has been omitted from the 2016 Rules. Rule 54 has been substituted, making penalties for violations subject to Sections 25A and 25B of the MMDR Act and the Mines and Minerals Adjudication of Penalties Rules, 2026. Schedule XII has been omitted from the Rules. The amendment mainly changes the way penalties will be applied under the concession rules. Instead of having separate penalty provisions within the rules, violations will now be addressed through the penalty mechanism provided under the MMDR Act and the Mines and Minerals Adjudication of Penalties Rules, 2026. This creates a common process for handling non-compliance in the mining sector. Why Has the Government Introduced These Changes? The Fourth Amendment is intended to align the Minerals (Other than Atomic and Hydro Carbons Energy Minerals) Concession Rules, 2016 with the recently introduced Mines and Minerals Adjudication of Penalties Rules, 2026. Instead of having separate penalty provisions under different mining rules, the Government is moving towards a single framework for adjudicating violations under the MMDR Act. The amendment is expected to: Create a uniform penalty mechanism for violations under the MMDR Act. Improve consistency in the enforcement of mining regulations. Remove outdated provisions that are no longer required under the revised legal framework. Simplify the penalty process by linking the concession rules with the new adjudication framework. Strengthen regulatory oversight while ensuring penalties are imposed through a defined legal process. Impact on Mining Lease Holders and Concession Holders The amendment does not introduce any new operational obligations for mining businesses. However, it changes the legal framework that will apply when there is a violation of the concession rules. The key impact on businesses includes: Mining lease holders, prospecting licence holders and composite licence holders will now be subject to the revised penalty framework under the MMDR Act. Businesses should review their internal compliance procedures to reduce the risk of violations that may attract penalties. Existing compliance records and regulatory documentation should be maintained accurately to support inspections or adjudication proceedings, where required. Compliance teams should familiarise themselves with the provisions of the Mines and Minerals Adjudication of Penalties Rules, 2026, as these rules will now govern the penalty process. Organisations should continue monitoring notifications issued by the Ministry of Mines to stay updated on any further changes to the mining regulatory framework. How Mining Businesses Should Prepare for Compliance The amendment does not change day-to-day mining operations. However, businesses should check their existing compliance practices and keep records and procedures updated according to the revised penalty provisions that will apply from 1 August 2026. Businesses should consider the following steps: Review mining lease, prospecting licence and composite licence obligations to ensure continued compliance. Familiarise compliance and legal teams with the Mines and Minerals Adjudication of Penalties Rules, 2026. Maintain accurate records of approvals, licences, returns and other statutory documents. Strengthen internal compliance monitoring to identify and address potential non-compliance at an early stage. Track future notifications issued under the MMDR Act that may impact concession holders. Benefits of the New Penalty Framework The revised rules provide clarity on how violations under the mineral concession rules will be handled. Mining companies will now have a defined process to understand the consequences of non-compliance and the applicable penalty provisions under the MMDR Act. Some of the key benefits include: Benefit How It Helps Uniform penalty mechanism Brings penalties under a single legal framework instead of separate rule-specific provisions. Greater regulatory clarity Clearly identifies the legal provisions that apply in case of violations. Improved enforcement Supports a more consistent approach to handling non-compliance. Better legal certainty Mining businesses can refer to a defined adjudication process for penalty matters. Stronger compliance culture Encourages businesses to strengthen internal compliance and record management. Difference between Earlier and Revised Penalty Framework The amendment changes the approach towards handling violations under the mineral concession rules. The key difference is the shift from rule-specific penalty provisions to a common adjudication mechanism. Area Earlier Framework Revised Framework Penalty process Managed through provisions available under individual rules Revised Framework Legal reference Separate rule-based provisions Sections 25A and 25B of the MMDR Act Enforcement approach Different mechanisms under different regulations Common framework for adjudication of penalties Compliance focus Following individual rule requirements Maintaining compliance with concession rules and penalty framework The revised approach is expected to create greater clarity for both regulators and businesses while improving consistency in enforcement. Is This a Positive Reform or an Additional Compliance Burden? The amendment is largely a regulatory alignment measure rather than a new compliance burden. It does not introduce additional licences, approvals or reporting requirements. Instead, it updates how violations of the concession rules will be addressed. Why the Amendment Is a Positive Step Reason Impact Uniform enforcement Creates consistency in the penalty process across the mining sector. Better legal framework Aligns the concession rules with the MMDR Act and the new adjudication rules. Greater transparency Provides a structured mechanism for dealing with regulatory violations. Simplified enforcement Removes the need for separate penalty provisions within the concession rules. Where Businesses Should Be Careful Area What It Means Compliance management Businesses should continue complying with concession conditions to avoid penalties. Documentation Accurate records will remain important during inspections or adjudication proceedings. Regulatory monitoring Companies should keep track of future amendments under the MMDR Act. Overall, the amendment is expected to improve regulatory consistency rather than increase the compliance burden for genuine mining businesses. How the Amendment Strengthens Regulatory Enforcement The revised rules change the way violations under the mineral concession rules will be handled. Penalties will now be decided according to the provisions of the MMDR Act and the Mines and Minerals Adjudication of Penalties Rules, 2026. The updated process will help in: Providing a clear procedure for dealing with violations. Reducing confusion about applicable penalty provisions. Making concession holders aware of the consequences of non-compliance. Creating a defined process for authorities while handling penalty cases. What Mining Companies Need to Monitor After 1 August 2026 Mining businesses should monitor regulatory developments after the implementation of the Fourth Amendment Rules. Important areas include: Notifications issued by the Ministry of Mines.  Changes under the MMDR Act and related rules.  Updates to penalty adjudication procedures.  New compliance requirements applicable to mineral concession holders.  Regulatory interpretations affecting mining operations. Key Takeaways for the Mining Sector The Minerals (Other than Atomic and Hydro Carbons Energy Minerals) Concession (Fourth Amendment) Rules, 2026 mainly focus on improving the penalty and enforcement framework under the mining regulations. The amendment does not change the process of obtaining mineral concessions or introduce additional operational requirements. Key takeaways include: The revised rules will come into effect from 1, August, 2026. Penalty provisions under the concession rules have been aligned with Sections 25A and 25B of the MMDR Act. The Mines and Minerals Adjudication of Penalties Rules, 2026, will now govern the penalty process for violations. Mining businesses should strengthen internal compliance monitoring and documentation practices. Lease holders and concession holders should regularly review regulatory updates issued under the MMDR framework. The amendment aims to create a more consistent and transparent approach towards mining law enforcement. Mining companies that maintain proper compliance systems and regulatory records will be better positioned to manage the revised enforcement framework. How Corpseed Can Support Mining Businesses The evolving mining regulatory framework requires businesses to stay updated with amendments, maintain proper documentation and manage compliance obligations effectively. Corpseed helps mining businesses understand regulatory changes and prepare for compliance requirements. 1. Regulatory Compliance Advisory Assist businesses in understanding changes under the MMDR Act and related mining rules. Guide compliance requirements applicable to mining lease holders and concession holders. 2. Documentation and Compliance Review Support businesses in reviewing existing regulatory records and documentation. Help identify gaps in compliance practices and improve internal processes. 3. Regulatory Update Monitoring Keep businesses informed about new notifications, amendments and policy changes issued by the Ministry of Mines. Help organisations understand how regulatory changes may impact their operations. 4. Compliance Process Support Assist businesses in developing structured compliance processes. Guide on maintaining records required for regulatory inspections and reviews. 5. Sector-Specific Advisory Support Help mining businesses evaluate regulatory requirements based on their activities. Provide compliance guidance to reduce risks associated with non-compliance and penalties. With the introduction of the Minerals (Other than Atomic and Hydro Carbons Energy Minerals) Concession (Fourth Amendment) Rules, 2026, businesses should focus on maintaining strong compliance practices and staying updated with regulatory developments. A proactive approach can help mining entities manage regulatory obligations effectively while supporting smooth operations.

Subject

Summary: An important press release has been issued by the Sikkim State Pollution Control Board (SPCB) regarding online consent management for pollution control clearances. This Sikkim SPCB OCMMS press release is essential reading for every industrial unit, healthcare facility, and project proponent based in Sikkim. The SPCB has identified a new, rising trend that poses a risk to all those seeking pollution control consents. Many applicants have been found to provide portal credentials to third parties, including external agents, unauthorized consultants, or even commercial cyber cafes, to handle their CTE and CTO applications.  This is very important, as these portal credentials will grant access to your establishment's record in the Online Consent Management & Monitoring System (OCMMS). Any misuse, mishandling, or careless handling of these credentials can delay the approval process or cause other integrity issues in the board's record. This compliance update has significantly changed the process of managing the CTE, CTO, and other statutory authorizations in Sikkim for manufacturers, healthcare facilities, and industrial entrepreneurs. It is time to understand the importance of compliance filings and the proper way to handle such issues, rather than blindly relying on others to do the work for you. Key Highlights The press release comes from the State Pollution Control Board Sikkim, under the Department of Forest & Environment, Government of Sikkim. It addresses the online submission process for Consent to Establish (CTE), Consent to Operate (CTO), and various statutory authorizations, including renewals. These consents are issued under the Water (Prevention and Control of Pollution) Act, 1974, and the Air (Prevention and Control of Pollution) Act, 1981. The Board has observed that several applicants depend heavily on external agents, unauthorized consultants, or commercial cyber cafes to operate their OCMMS portal accounts. Login IDs and passwords generated on OCMMS after registration must be retained strictly by the applicants themselves. The same login credentials must be used for all future interactions, including CTE/CTO renewals, expansion requests, and annual waste management authorizations. The Board has explicitly clarified that no third-party agents, private consultants, or computer/cyber cafes have been empanelled, authorized, or recognized by it. Applicants may still choose to engage such entities at their own discretion, but the Board will not be responsible for fees charged or actions taken by them. No additional or separate service charge is required to file applications, apart from the government-prescribed statutory Consent or Authorization fee paid through the official portal. The Board has made step-by-step video tutorials and detailed user manuals available on its official website to help applicants navigate the process on their own. Applicants are urged to follow official guidelines, secure their digital access, and avoid engaging intermediaries. For technical difficulties, applicants have been directed to the designated Help Desk or the official Board website. The Regulatory Framework This press release concerns two main environmental acts applicable across India, including Sikkim. The Water (Prevention and Control of Pollution) Act, 1974 mandates that industries, establishments, and projects that release or are capable of releasing trade effluents obtain consent from the concerned State Pollution Control Board before setting up and operating. Similarly, the Air (Prevention and Control of Pollution) Act, 1981 also mandates obtaining consent for units emitting air pollutants, especially those that fall under the category of scheduled/notifiable industries. In accordance with the above-mentioned acts, there are two steps involved in getting the approvals: Consent to Establish (CTE): Consent obtained before the physical establishment of the unit. Consent to Operate (CTO): Permission granted once the unit is constructed and ready to function, confirming that actual pollution control systems are in place and operating as approved. For Sikkim, the processing of such consents, their renewals, and authorization related to waste management is done through an online portal called the Online Consent Management & Monitoring System (OCMMS). This notification is issued by the Member Secretary, State Pollution Control Board , Sikkim, which functions under the Department of Forest & Environment, Government of Sikkim. The scope of this notification covers all types of applicants who deal with OCMMS, i.e., industrialists, project proponents, and healthcare facilities. Healthcare facilities have been specifically mentioned, as hospitals, nursing homes, diagnostic centres, and clinics also require pollution-related consents and authorizations, particularly for effluent discharge and the disposal of biomedical or hazardous waste, in addition to industrial establishments. What Has Changed? Technically, this press release does not introduce a new law or amend the Water Act or Air Act. It issues a formal administrative clarification on how the existing OCMMS portal must be used. It draws a firm line around who is authorized to interact with it on an applicant's behalf. Aspect Earlier Practice (Observed by Board) Current Clarified Position Portal login handling Many applicants shared credentials with agents, consultants, or cyber cafes Credentials must be retained strictly by the applicant only Recognition of third parties Some applicants assumed agents or cyber cafes were Board-approved Board has explicitly stated no such entity is empaneled, authorized, or recognized Responsibility for third-party actions Ambiguous, often assumed to rest with the Board or portal Board bears no responsibility for fees, representations, or actions of third parties Service charges Some applicants believed external charges were mandatory or official No separate service fee is authorized beyond the statutory government fee paid online Applicant guidance Limited formal direction on self-filing Board has provided video tutorials and manuals for self-help filing The fundamental change is that of accountability. In the past, most applicants regarded agents and cyber cafes as an unofficial but acceptable part of the application process. However, the Board has made it clear to everyone that this is not an official route and any liability connected with it is fully that of the applicant. Implementation Timeline and Norms This is a press release, not a phased regulation, so there is no separate transition period or grace window before it takes effect. The clarifications take effect immediately from the date of issue. Effective Date: From the date of the press release itself. Applicability: All existing and future applicants using OCMMS for CTE, CTO, renewals, expansion applications, and annual waste management authorizations under the Water Act and Air Act in Sikkim. Required Actions for Applicants: It would be advisable for the applicants to immediately take an inventory of people who already have access to the OCMMS login credentials of the applicant, change the password if it was already provided to any external person, and make sure that any future filing will be done using credentials that no one outside the establishment will access. No Deadline for Compliance in the Strict Sense of the Word: This notice does not contain any filing requirement, and hence, there is no deadline for compliance in its strict sense of the word. Why This Was Implemented? It must be noted that the Board's stated purpose in issuing the press release is quite simple and clear: the protection of applicants and the maintenance of the integrity of the regulatory process. Multiple goals lie beneath this statement. Data and Digital Security: It goes without saying that OCMMS contains sensitive information about establishments – the consent history, compliance status, applications, and other personal details. Therefore, if cyber cafes or unregistered agents use the login details, there is a great risk of modifications, submission errors, and misuse of corporate data. Ease of Doing Business: As is clear from the text, the clarification that the submission can be done through the portal alone and does not require mandatory use of intermediaries is one of the Board's attempts to promote a self-service, transparent filing culture, which is an important goal in the Indian context of the ease of doing business. Consumer and Applicant Protection: It is very likely that the applicants paid additional money to agents to submit their applications and assumed these payments were mandatory. Therefore, clarifying that they must pay only for the services provided, not a separate service fee, protects them from deception. Regulatory Integrity: Third parties operating the account and submitting applications on behalf of an establishment do not help create a transparent audit trail of who actually uses it. Public Interest and Trust: Since CTE and CTO approvals concern environmental protection, air and water quality, and public health in the case of healthcare facilities, they are also an important public-interest task. Impact on Businesses However, the effect of the clarification varies somewhat according to the nature of the business, although the basic idea remains the same: secure your credentials. Manufacturing Units & Industrial Units: Manufacturers or industrial units that have submitted their CTE before construction and CTO before commissioning shall ensure that whoever handles the OCMMS account on behalf of the company, whether a compliance officer of the unit itself or the owner, has complete control over the login credentials. Passing them to a plant-level contractor or any outside agent without supervision is not advisable. Healthcare Facilities: All hospitals, clinics, diagnostic centers, and nursing homes that require consent for effluent discharge and biomedical waste management need to understand this clarification as an instruction to obtain their portal access credentials on their own. Project Proponents and New Entrants: Businesses setting up new projects in Sikkim who may be filing for CTE for the first time should register directly on OCMMS and avoid the temptation to use route-through registration via a cyber cafe purely for convenience. MSMEs and Startups: Smaller businesses without a dedicated compliance team are often the ones most likely to depend on cyber cafes or informal agents due to limited familiarity with online government portals. This notice is particularly relevant for them, since they stand to lose the most if their compliance profile is compromised or mismanaged by an unaccountable third party. Large Companies: Large companies will have EHS (Environment, Health, and Safety) personnel within the company, but when large enterprises have multiple locations, responsibility for accessing the portal may be delegated informally to junior employees and site-level vendors. This would be an excellent time to develop an SOP outlining who is responsible for accessing OCMMS in the company. Exporter, OEM, and Manufacturer with Supply Chain Dependencies: In companies where downstream customers require documentation on environmental consents, delays or disputes related to portal access will disrupt the documentation process. Across all these categories, the operational impact is really about internal governance: who holds the login, who is accountable for what gets submitted, and how the paper trail is maintained. How Businesses Can Stay Compliant? Following this clarification, a practical compliance roadmap for applicants in Sikkim should include the following steps. Audit Current Portal Access: Check who currently has knowledge of, or access to, your OCMMS login credentials. If any external agent, consultant, or cyber cafe has previously handled your account, treat this as a red flag requiring immediate action. Reset and Secure Your Credentials: Reset your OCMMS password if there is any possibility that it has been disseminated beyond the establishment. Secure your login details and, if possible, restrict internal access to them rather than allowing informal circulation amongst your employees. Select a Point Person: Appoint a specific individual or a small internal team, such as a compliance officer or an environment manager, to handle OCMMS filings, renewals, and communications. Consult Official Materials First: Use the video tutorials and manuals provided on the Board's official website before concluding that external assistance is needed. Many common problems experienced by those new to filing can be resolved with these self-help materials. Check Fee Payments: Verify that your payments for Consent or Authorization are made securely via the portal gateway and that you are not being asked to pay a service charge in addition to the required fee. The Board has clearly stated that no additional service charge may be requested. Keep Application and Renewal Timelines Organized: Maintain an internal record of the dates of your CTE and CTO applications, renewal dates, expansion requests, and waste management authorization filings, as you will use the same credentials multiple times for these. Contact the Official Help Desk for Portal Technical Problems: For any portal-related technical issues, use the Board's official help desk rather than contacting any unofficial intermediaries. Seek Professional Assistance for Your Documentation: Though access to the portal and management of credentials need to be internal processes, the process of compliance, which includes the preparation of technical documentation, effluent and emissions data, waste management plans and the supporting reports for CTE and CTO applications, is where many businesses benefit from expert regulatory consultants. Common Mistakes to Avoid Sharing login credentials for the OCMMS with cyber cafes for temporary convenience. Taking it for granted that all consultants representing themselves as having been empanelled by the Board are indeed officially empanelled, without actually confirming this from the Board. Payment of unspecified or ambiguous "service charges" other than the statutory portal charges. Allowing renewal deadlines to pass since the login credentials were with a third party that cannot now be contacted. Not updating the contact information associated with the OCMMS account after important staff changes. Benefits for Businesses That Comply Many benefits can accrue to businesses that align with the guidance above. Improved data management: Maintaining exclusive access to your OCMMS account ensures that your data is not altered or misrepresented in terms of regulatory compliance. Avoidance of unnecessary expenses: Refraining from paying unofficial service charges helps businesses avoid costs the Board may not have required. Consistency in renewals: Since the same data is required to fill subsequent reports, having control over it means that renewing business licenses or expanding will not be hampered by reliance on an outside agency. Good compliance record: Having control over your compliance record makes it easier to trace and defend during inspections and audits. Ease in planning to expand: Companies that want to expand their operations or add new branches do not have to trace and gather data from an outside agency. Businesses that align with this clarified guidance stand to gain in several practical ways. Improved trust with regulators: Direct, accountable engagement with the Board, backed by the applicant's own credentials, supports a more cooperative regulatory relationship over the long term. Right Decision or Additional Burden? From an objective perspective, this clarification is more about safe housekeeping practices than adding another regulation. No new costs, approvals, or documentation are required. However, what is required is a change in attitude. The Benefits: The notice eliminates a true security loophole. Businesses that were unaware that someone else had access to their information have a signed written statement from the Board confirming that no such relationship exists. This ensures the safety of the applicant’s personal and financial information. The Challenges: For businesses that have relied on cyber cafes or informal local agents purely because they lack in-house digital literacy or a dedicated compliance resource, this shift does require some adjustment. Someone within the organization now needs to take ownership of the portal, learn the filing process, or work with a properly engaged advisor while retaining direct control of credentials. Compliance Costs: There are no new statutory costs associated with this notice. If anything, businesses may save money previously spent on unofficial service charges that were never required. Business Readiness: Larger, more organized businesses will find this an easy adjustment. Smaller businesses and first-time applicants may need a brief internal transition period to become familiar with OCMMS, which is exactly why the Board has provided tutorials and manuals. Long-Term Impact: Over time, this kind of clarification tends to improve the overall quality and reliability of the regulatory filing ecosystem, benefiting compliant businesses by reducing confusion, fraud risk, and administrative disputes tied to unauthorized intermediaries. Business Opportunities Created Although the notice is more protective than an opportunity-creation tool from the business standpoint, there are several tangible options available for enterprises operating in Sikkim. Improved internal compliance capacity: Businesses that build internal expertise in OCMMS will be better positioned to handle future applications, renewals, and other growth-related consents much more quickly. Improved engagement with professionals: The removal of unauthorized agents provides an opportunity for businesses to engage properly regulated consultants for all required documentation and reporting through the portal. Decreased dispute risk related to expansion or investment: This is possible due to the applicant's creation of a clear compliance record. Better positioning for multi-state operations: Businesses operating across states can use this as a template to formalize similar internal SOPs for other State Pollution Control Board portals, not just Sikkim's OCMMS. Why Choose Corpseed for Regulatory Support? Corpseed helps manufacturers, hospitals, and promoters in India with drafting and managing the substance of filings for compliance, including CTE, CTO, and other statutory clearances, without needing to have control over the login credentials of the applicant with their respective government portals. The value added by Corpseed lies in the parts of the process that require regulatory expertise, i.e., understanding applicability under the Water Act and Air Act, drafting technical documents, properly structuring waste management and effluent information, and ensuring that filings are accurate before they are submitted. All of this is separate yet fully compliant with the clarification provided by the Board that applicants need to retain and control their own OCMMS login. Companies partnering with Corpseed will get access to regulatory consultants who know state-specific portal requirements, structured documentation support, assistance with communicating with government departments for follow-ups and clarifications, help with renewals and expansion filings, pan-India services for companies operating across different states, and a process with set timelines. Applicants will thus be able to seek guidance from experts on filing while still maintaining control over their portal access, as the Board has clarified. Corpseed's Core Message Regulatory clarity is only useful if it is acted upon correctly. This press release is a clear signal from the Sikkim State Pollution Control Board that applicants themselves must remain in control of their digital compliance footprint. At the same time, the substance of getting CTE, CTO, and related approvals right still requires careful, informed preparation. Companies that attempt to manage environmental compliance documentation independently may face delays due to incomplete applications, missed renewals, or a lack of understanding of the necessary technicalities. On the other hand, providing access to a portal by an unvetted third party is no longer subject to the Board's approval. The practical path forward is to keep account access strictly internal while obtaining professional support for the documentation and the application's technical accuracy. This reduces both the security risk flagged by the Board and the compliance risk of an incomplete or delayed filing. Businesses that want structured, expert support in preparing and managing their environmental compliance filings without compromising credential security can reach out to Corpseed's regulatory team for guidance.